|1.07||0||0.00||Vol 269.89K||1Y Perf -62.72%|
|Dec 7th, 2023 16:00 DELAYED|
|- -%||- -|
|Target Price||13.71||Analyst Rating||Moderate Buy 2.14|
|Potential %||1.18K||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★+ 43.25|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★ 39.34|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||13.17||Earnings Rating||—|
|Market Cap||86.29M||Earnings Date||7th Nov 2023|
Today's Price Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.61|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||741.04K|
|Avg. Monthly Volume||438.64K|
|Avg. Quarterly Volume||326.24K|
ADC Therapeutics SA (NYSE: ADCT) stock closed at 1.07 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 269.89K shares and market capitalization of 86.29M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 138 people. ADC Therapeutics SA CEO is .
The one-year performance of ADC Therapeutics SA stock is -62.72%, while year-to-date (YTD) performance is -72.14%. ADCT stock has a five-year performance of %. Its 52-week range is between 0.359908 and 5.75, which gives ADCT stock a 52-week price range ratio of 13.17%
ADC Therapeutics SA currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 2.63, a price-to-sale (PS) ratio of 2.01, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -28.39%, a ROC of -58.26% and a ROE of -113.68%. The company’s profit margin is -93.96%, its EBITDA margin is -95.10%, and its revenue ttm is $140.11 Million , which makes it $1.80 revenue per share.
Of the last four earnings reports from ADC Therapeutics SA, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. ADC Therapeutics SA’s next earnings report date is -.
The consensus rating of Wall Street analysts for ADC Therapeutics SA is Moderate Buy (2.14), with a target price of $13.71, which is +1 181.31% compared to the current price. The earnings rating for ADC Therapeutics SA stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ADC Therapeutics SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ADC Therapeutics SA has a Neutral technical analysis rating based on Technical Indicators (ADX : 22.15, ATR14 : 0.11, CCI20 : 133.08, Chaikin Money Flow : -0.03, MACD : 0.09, Money Flow Index : 89.35, ROC : 50.64, RSI : 67.89, STOCH (14,3) : 80.57, STOCH RSI : 0.69, UO : 61.04, Williams %R : -19.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ADC Therapeutics SA in the last 12-months were:
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.